GBM patients ; best supportive care
While scrolling through the SNO site, I came across a short paper that examined what the outcomes were for patients diagnosed with GBM and were recommended best supportive care i.e. no treatment.
Of the 115 patients studied, all died within 32 weeks with a median of 8 weeks survival. Less than 10% survived for more than 20 weeks.
While patients who undergo treatment survive a little longer (avg 6 months), they eventually succumb to the disease.
What a sobering read, and something to really put into perspective what CHM are trying to achieve with this CLTX trial.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $50.77K | 12.69M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2602327 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 18629873 | 23 |
View Market Depth
| Last trade - 15.15pm 25/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |